A Phase 2A, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety and Efficacy of TRC150094 in Increasing Insulin Sensitivity in Male Patients With Increased Cardiometabolic Risk.

Trial Profile

A Phase 2A, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety and Efficacy of TRC150094 in Increasing Insulin Sensitivity in Male Patients With Increased Cardiometabolic Risk.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs TRC 150094 (Primary)
  • Indications Glucose intolerance; Lipid metabolism disorders; Metabolic syndrome; Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
    • 25 Sep 2013 Primary endpoint 'Insulin-sensitivity' has not been met.
    • 11 Mar 2013 New source identified and integrated (Clinical Trials Registry - India: CTRI2013-03-003470).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top